Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Vaccines and Program Development

Newsfile November 30, 2021

Defence Therapeutics (CSE:DTC) announces agreement with the Lady Davis Institute

John Ballem  November 23, 2021

Defence Therapeutics Cancer Vaccine AccuVac-D001 Manufacturing Targets Melanoma and Breast Cancer

Newsfile November 23, 2021

Defence Therapeutics (CSE:DTC) appoints Dr. Riam Shammaa to its board of directors

John Ballem  November 9, 2021

Defence Therapeutics Appoints Dr. Riam Shammaa to Its Board of Directors

Newsfile November 9, 2021

Defence Therapeutics Reports Successful Completion of Its COVID-19 Vaccine AccuVAC-PT001 Toxicology Studies in Rabbits

Newsfile November 3, 2021

Today’s market summary: energy shortages dampen economic recovery

Trevor Abes  October 14, 2021

Defence Therapeutics Accum Variants Increases Potency of T-Deruxtecan Antibody-Drug Conjugate

John Ballem  October 13, 2021

Defence Therapeutics Accum(TM) Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer

Newsfile October 13, 2021

Today’s market summary: oil prices boost energy and bank stocks

Julia Kennedy  October 6, 2021

Defence Therapeutics (CSE:DTC) prepares for phase I trial of AccuVAC-D002

John Ballem  October 6, 2021

Defence Therapeutics Prepares for Phase I Trial to Test Its DC Cancer Vaccine, AccuVAC-D002, Against Melanoma

Newsfile October 6, 2021

Defence Therapeutics (CSE:DTC) is preparing to initiate a Phase I trial for one of its leading AccuTOX candidates against breast cancer

John Ballem  September 29, 2021

Defence Therapeutics to Finalize Its Objectives to Initiate a Phase I Trial Against Breast Cancer

Newsfile September 29, 2021

Top 5 Stories of the Week: Defence Therapeutics (CSE:DTC), Next Hydrogen (TSXV:NXH), XTM (CSE:PAID), PyroGenesis (TSX:PYR), and Alpha Cognition (TSXV:ACOG)

Julia Kennedy  September 24, 2021

Today’s markets summary: Stock indices rally after election uncertainty

Julia Kennedy  September 22, 2021

Defence Therapeutics Announces Development of Intranasal COVID-19 Vaccine Formulation

John Ballem  September 20, 2021

Defence Therapeutics Successfully Engineered and Tested a Novel Intranasal COVID-19 Vaccine Formulation in Animals

Newsfile September 20, 2021

CSE Bulletin: Index - CSE 25 Index Quarterly Rebalancing

Newsfile September 17, 2021

Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model

Newsfile September 14, 2021